Clinical Results | XOLAIR® (omalizumab),Clinical Results | XOLAIR® (omalizumab),First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial -,Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial - The Lancet,The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK - Vasiliadou - 2024 - International Journal of Cancer - Wiley Online Library